Isatuximab in combination with atezolizumab (anti-PD-L1) is being studied for the treatment of platinum-refractory recurrent/metastatic SCCHN, platinum-resistant/refractory epithelial ovarian cancer (EOC), recurrent glioblastoma multiforme (GMB), and hepatocellular carcinoma (HCC; ClinicalTrials.gov, NCT03637764). The gene discussed is CD274; the disease is hepatocellular carcinoma.